• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

对Ta期和T1期膀胱移行细胞癌患者进行至少20年的随访,观察其多次复发、进展与预后之间的关系。

The relationship among multiple recurrences, progression and prognosis of patients with stages Ta and T1 transitional cell cancer of the bladder followed for at least 20 years.

作者信息

Holmäng S, Hedelin H, Anderström C, Johansson S L

机构信息

Department of Urology, Sahlgrenska University Hospital, Göteborg, Sweden.

出版信息

J Urol. 1995 Jun;153(6):1823-6; discussion 1826-7.

PMID:7752327
Abstract

A retrospective study was done on 176 patients with primary stages Ta and T1 bladder cancer treated between 1963 and 1972. One patient was lost to followup after 6 years, while the remainder were followed to death or for at least 20 years. In 1993, 13 patients had no evidence of disease, 39 died of bladder cancer and 123 died of intercurrent disease. Of 77 patients with a primary noninfiltrating tumor and 99 with a primary lamina propria invasive tumor 9 (11%) and 30 (30%), respectively, died of bladder cancer. Recurrences were noted on 10 or more cystoscopic studies in 16 patients and 10 died of bladder cancer 3.5 to 19 years after the primary transurethral resection. A total of 14 patients received repeated thiotepa instillations, all continued to have recurrences and 10 subsequently died of bladder cancer. Only 1 upper tract tumor was diagnosed on routine followup excretory urography. Invasive transitional cell carcinoma of the bladder developed in only 1 of 59 patients who had been tumor-free for 5 years. The results indicate that patients with recurrences on 10 or more cystoscopic studies will continue to have recurrences until death or cystectomy. Recurrence more than 4 years after the primary tumor operation is another ominous sign. Repeated thiotepa instillations did not influence the course of the disease in patients with a history of multiple recurrences. Followup cystoscopy may be discontinued 5 to 10 years after the last recurrence, at least in patients with a solitary low grade primary tumor. Routine followup urographic studies are neither cost-effective, clinically indicated nor justified in patients with superficial bladder cancer.

摘要

对1963年至1972年间接受治疗的176例原发性Ta期和T1期膀胱癌患者进行了回顾性研究。1例患者在6年后失访,其余患者随访至死亡或至少20年。1993年,13例患者无疾病证据,39例死于膀胱癌,123例死于并发疾病。在77例原发性非浸润性肿瘤患者和99例原发性固有层浸润性肿瘤患者中,分别有9例(11%)和30例(30%)死于膀胱癌。16例患者在10次或更多次膀胱镜检查中发现复发,其中10例在初次经尿道切除术后3.5至19年死于膀胱癌。共有14例患者接受了反复的噻替派灌注,均持续复发,其中10例随后死于膀胱癌。在常规随访排泄性尿路造影中仅诊断出1例上尿路肿瘤。在59例已无肿瘤5年的患者中,仅1例发生了浸润性膀胱移行细胞癌。结果表明,在10次或更多次膀胱镜检查中出现复发的患者将继续复发直至死亡或接受膀胱切除术。原发性肿瘤手术后4年以上复发是另一个不祥之兆。反复的噻替派灌注对有多次复发史的患者的疾病进程没有影响。至少在孤立性低级别原发性肿瘤患者中,最后一次复发后5至10年可停止随访膀胱镜检查。对于浅表性膀胱癌患者,常规随访尿路造影检查既不具有成本效益,临床上也无指征且不合理。

相似文献

1
The relationship among multiple recurrences, progression and prognosis of patients with stages Ta and T1 transitional cell cancer of the bladder followed for at least 20 years.对Ta期和T1期膀胱移行细胞癌患者进行至少20年的随访,观察其多次复发、进展与预后之间的关系。
J Urol. 1995 Jun;153(6):1823-6; discussion 1826-7.
2
Recurrence, progression and success in stage Ta grade 3 bladder tumors treated with low dose bacillus Calmette-Guerin instillations.低剂量卡介苗灌注治疗Ta3期膀胱肿瘤的复发、进展及疗效
J Urol. 2000 Jan;163(1):63-7.
3
Clinical panurothelial disease in patients with superficial bladder tumors: therapeutic implications.浅表性膀胱肿瘤患者的临床全尿路上皮疾病:治疗意义。
J Urol. 2002 May;167(5):2007-11.
4
Superficial transitional cell carcinoma of the ureteral orifice: higher risk of developing subsequent upper urinary tract tumors.输尿管口浅表移行细胞癌:发生后续上尿路肿瘤的风险更高。
Int J Urol. 2006 Jun;13(6):682-5. doi: 10.1111/j.1442-2042.2006.01385.x.
5
Prognostic factors for primary superficial transitional cell carcinoma of the bladder: a retrospective cohort study.膀胱原发性浅表性移行细胞癌的预后因素:一项回顾性队列研究。
Chin Med J (Engl). 2006 Nov 5;119(21):1821-8.
6
Risk factors for upper tract recurrence in patients undergoing long-term surveillance for stage ta bladder cancer.对Ta期膀胱癌患者进行长期监测时上尿路复发的危险因素。
J Urol. 2006 Jan;175(1):74-7. doi: 10.1016/S0022-5347(05)00071-6.
7
Clinical outcome of tumor recurrence for Ta, T1 non-muscle invasive bladder cancer from the data on registered bladder cancer patients in Japan: 1999-2001 report from the Japanese Urological Association.根据日本登记膀胱癌患者的数据得出的Ta、T1期非肌层浸润性膀胱癌肿瘤复发的临床结果:日本泌尿外科学会1999 - 2001年报告
Int J Urol. 2009 Mar;16(3):279-86. doi: 10.1111/j.1442-2042.2008.02235.x. Epub 2009 Jan 20.
8
Intravesical bacillus Calmette-Guerin therapy for stage T1 grade 3 transitional cell carcinoma of the bladder: recurrence, progression and survival in a study of 57 patients.膀胱内卡介苗治疗T1期3级膀胱移行细胞癌:57例患者的复发、进展及生存情况研究
J Urol. 2003 Jun;169(6):2110-2. doi: 10.1097/01.ju.0000066840.42991.4a.
9
Ta T1 low and intermediate transitional cell carcinoma of the bladder: recurrence rates and the timing of check cystoscopies within the first year.膀胱Ta T1期低级别和中级别的移行细胞癌:复发率及第一年膀胱镜检查的时间安排
Urol Int. 2008;80(2):124-8. doi: 10.1159/000112600. Epub 2008 Mar 19.
10
The results of concurrent chemo-radiotherapy for recurrence after treatment with bacillus Calmette-Guérin for non-muscle-invasive bladder cancer: is immediate cystectomy always necessary?卡介苗治疗非肌层浸润性膀胱癌后复发的同步放化疗结果:是否总是需要立即进行膀胱切除术?
BJU Int. 2009 Jul;104(2):179-83. doi: 10.1111/j.1464-410X.2008.08299.x. Epub 2008 Dec 23.

引用本文的文献

1
Description of a cruciferous vegetable intervention trial to test the efficacy of a maintenance component to reduce bladder cancer recurrence and progression.一项十字花科蔬菜干预试验的描述,该试验旨在测试一种维持成分降低膀胱癌复发和进展的疗效。
Contemp Clin Trials. 2025 Jul 30;156:108036. doi: 10.1016/j.cct.2025.108036.
2
Double-J stenting during TURBT increases risk of metachronous upper tract urothelial carcinoma.经尿道膀胱肿瘤电切术(TURBT)期间置入双J管会增加异时性上尿路尿路上皮癌的风险。
BMC Urol. 2025 Jun 2;25(1):146. doi: 10.1186/s12894-025-01828-1.
3
Metastasis development in non-muscle-invasive bladder cancer.
非肌层浸润性膀胱癌中的转移发展
Nat Rev Urol. 2024 Nov 20. doi: 10.1038/s41585-024-00963-y.
4
Cholesterol Metabolism and Urinary System Tumors.胆固醇代谢与泌尿系统肿瘤
Biomedicines. 2024 Aug 12;12(8):1832. doi: 10.3390/biomedicines12081832.
5
Outcomes of a Dietary Intervention to Reduce Bladder Cancer Recurrence and Progression in Survivors of Non-Muscle-Invasive Bladder Cancer.膳食干预降低非肌肉浸润性膀胱癌幸存者膀胱癌复发和进展的结果。
J Natl Compr Canc Netw. 2024 Feb 26;22(2):e237086. doi: 10.6004/jnccn.2023.7086.
6
URINE CYTOLOGY AND AXILLARY TESTING FOR INTERPRETATION AND FOLLOW-UP OF URINARY TUMORS.尿液细胞学检查和腋窝检测用于解读和随访泌尿系统肿瘤。
Acta Clin Croat. 2022 Nov;61(3):505-510. doi: 10.20471/acc.2022.61.03.16.
7
Farnesoid X Receptor Overexpression Decreases the Migration, Invasion and Angiogenesis of Human Bladder Cancers via AMPK Activation and Cholesterol Biosynthesis Inhibition.法尼醇X受体过表达通过激活AMPK和抑制胆固醇生物合成降低人膀胱癌的迁移、侵袭和血管生成。
Cancers (Basel). 2022 Sep 9;14(18):4398. doi: 10.3390/cancers14184398.
8
Risk score-based substratification improves surveillance costs after transurethral resection of bladder tumor in patients with primary high-risk non-muscle-invasive bladder cancer.基于风险评分的亚组分层可改善原发性高危非肌肉浸润性膀胱癌患者经尿道膀胱肿瘤切除术后的监测成本。
Sci Rep. 2022 Aug 12;12(1):13786. doi: 10.1038/s41598-022-17973-8.
9
Cruciferous Vegetable Intervention to Reduce the Risk of Cancer Recurrence in Non-Muscle-Invasive Bladder Cancer Survivors: Development Using a Systematic Process.十字花科蔬菜干预降低非肌层浸润性膀胱癌幸存者癌症复发风险:基于系统流程的开发
JMIR Cancer. 2022 Feb 15;8(1):e32291. doi: 10.2196/32291.
10
TRIB3 Promotes the Malignant Progression of Bladder Cancer: An Integrated Analysis of Bioinformatics and Experiments.TRIB3促进膀胱癌的恶性进展:生物信息学与实验的综合分析
Front Genet. 2021 Mar 26;12:649208. doi: 10.3389/fgene.2021.649208. eCollection 2021.